NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...
Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...
When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Zacks.com on MSN5h
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Its lead candidate, VK2735, will start its phase 3 clinical trials soon after the company meets with regulators at the Food and Drug Administration to discuss a few details; assuming standard ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...
ByInvesting.com • Oct 25, 2024 Viking Therapeutics stock holds Buy rating with focus on upcoming oral VK2735 data at Obesity Week On Thursday, BTIG maintained a Buy rating on Viking Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback